Is There An Opportunity With Delfi Limited's (SGX:P34) 42% Undervaluation?
Delfi (SGX:P34) Has Announced A Dividend Of $0.0302
Delfi (SGX:P34) Strong Profits May Be Masking Some Underlying Issues
Delfi Limited's (SGX:P34) robust recent earnings didn't do much to move the stock. We think this is due to investors looking beyond the statutory profits and being concerned with what they see. SG
Delfi's Earnings Margins May Face Minimal Pressure From High Cocoa Prices -- Market Talk
0713 GMT - Delfi's earnings margins may face minimal pressure from high prices of its key ingredient cocoa, RHB Research analyst Alfie Yeo says in a research report. The Singapore-listed chocolate con
Delfi (SGX:P34) Is Due To Pay A Dividend Of $0.0302
Delfi Limited Announces Board Leadership Transition
DELFI Diagnostics to Present at American Association for Cancer Research Annual Meeting
DELFI Diagnostics, Inc. (PRNewsfoto/DELFI Diagnostics) FirstLook Lung is a new blood test that offers a convenient, accessible, and personalized approach to enhance lung cancer screening. Firs
Delfi Faces Earnings Hit From Higher Raw Material Prices -- Market Talk
0415 GMT - Delfi faces an earnings hit from higher raw material prices, RHB Research analyst Alfie Yeo says, noting that the Singapore-listed company's 2023 revenue growth and operating margins missed
Delfi Ltd. Target Price Lowered to S$1.33 From S$1.55 by RHB Research >P34.SG
Delfi Ltd. Target Price Lowered to S$1.33 From S$1.55 by RHB Research >P34.SG
Shareholders in Delfi (SGX:P34) Are in the Red If They Invested Five Years Ago
Delfi Faces Earnings Hit From Higher Commodity Prices -- Market Talk
0212 GMT - Delfi faces earnings hit from higher commodity prices, UOB Kay Hian analysts say in a research note as they lower the stock's rating to hold from buy and cut the target to S$1.07 from S$1.7
Delfi Cut to Hold From Buy by UOB Kay Hian >P34.SG
Delfi Cut to Hold From Buy by UOB Kay Hian >P34.SG
Delfi Limited's (SGX:P34) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Delfi (SGX:P34) has had a rough three months with its share price down 18%. However, a closer look at its sound financials might cause you to think again. Given that fundamentals usually drive long-
CGS International Adjusts Delfi's Price Target to SG$1.47 From SG$1.56, Keeps at Add
10:48 PM EST, 03/03/2024 (MT Newswires) -- CGS International Adjusts Delfi's Price Target to SG$1.47 From SG$1.56, Keeps at Add Price (SGD): S$0.96, Change: S$-0.01, Percent Change: -1.04%
Delfi (SGX:P34) Will Pay A Dividend Of $0.0302
Delfi Limited: A Sweet Opportunity for Investors Amidst Market Leadership and Strategic Growth
Delfi Full Year 2023 Earnings: EPS: US$0.076 (Vs US$0.072 in FY 2022)
Delfi's H2 2023 Attributable Profit Slides 14% Amid Increased Costs
Delfi (SGX:P34) saw a more than 14% decline in attributable profit for the second half of 2023 after selling, distribution, and finance costs increased from a year ago. The chocolate company's profit
Multi-Cancer Diagnostic Tests Market Outlook 2024-2029, Featuring Profiles of Anchordx Medical, Burning Rock Biotech, Delfi Diagnostics, Exact Sciences, Freenome, Genecast, Grail and Guardant Health
DELFI Collaborates With Immunocore Holdings For Exploring Use Of DELFI-TF Cancer Monitoring Assay
DELFI Collaborates With Immunocore Holdings For Exploring Use Of DELFI-TF Cancer Monitoring Assay
No Data